EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602)

Jonathan R Strosberg iD, Tyler Zemla, Susan Geyer, Sydney Pulsipher, Fang-Shu Ou, Spencer Behr, Nitya Raj iD, Namrata Vijayvergia, Arvind Dasari iD, Eileen M O'Reilly, Jeffrey A Meyerhardt, Edward M Wolin und 2 weitere

Endocrine-Related Cancer · 01.01.2026 · 33 (1)

DOI: 10.1530/erc-25-0415 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Endocrine-Related Cancer, online erschienen am 12.01.2026. Verfasst von Jonathan R Strosberg und 13 weiteren Autor:innen. Beteiligte Einrichtung: Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pyridines, Anilides, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Well-differentiated grade 3 neuroendocrine tumors (NETs) have recently been described as a distinct category, and randomized data regarding efficacy of therapy for these patients are scarce. In the phase 3 CABINET trial, cabozantinib improved PFS compared with placebo in patients with advanced, previously treated, progressive extra-pancreatic NETs (epNETs) and pancreatic NETs (pNETs) of all grades. Here, we evaluate if these results remain consistent in a subgroup of patients with well-differentiated G3 NETs. Patients with locally advanced or metastatic epNETs or pNETs were randomized 2:1 in independent cohorts to receive cabozantinib 60 mg daily vs placebo. We analyzed outcomes of the subset of patients with G3 NETs (Ki-67 > 20%), combining patients in the pNET and epNET cohorts due to small sample sizes. Twenty-four patients had G3 NETs, 16 randomized to cabozantinib and 8 to placebo. Primary sites included pancreas (n = 12), GI tract (n = 7), unknown primary sites (n = 3), and lung/thymus (n = 2). Median PFS for patients with G3 NETs treated with cabozantinib was 7.9 vs 3 months with placebo (HR = 0.15, 95% CI: 0.04–0.57, 1-sided log-rank P = 0.0034). The confirmed overall radiographic response rate was 25% (4/16) with cabozantinib vs 0% (0/8) with placebo. Safety outcomes were consistent with published data for the trial as a whole. Subset analysis of the CABINET trial showed improved PFS associated with cabozantinib vs placebo for G3 NETs of pancreatic and extra-pancreatic origin. Despite limited numbers, these results suggest that cabozantinib can be an effective option for patients with advanced G3 NETs. ClinicalTrials.gov Identifier: NCT03375320.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPyridinesAnilidesAntineoplastic AgentsHumansMaleFemaleMiddle AgedAgedAdultNeoplasm Grading

Stichwörter der Autor:innen

cabozantinibextra-pancreatic neuroendocrine tumorgrade 3 neuroendocrine tumorpancreatic neuroendocrine tumor

Substanzen

cabozantinibPyridinesAnilidesAntineoplastic Agents

Autor:innen und Institutionen

  • Moffitt Cancer Center, Tampa, Florida, USA.
  • Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, USA.
  • University of California, San Francisco, California, USA.
  • Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Jonathan R Strosberg, Nitya Raj, Arvind Dasari

Förderung

  • NCI NIH HHS

Zitieren

APA

Strosberg, J. R., Zemla, T., Geyer, S., Pulsipher, S., Ou, F. S., Behr, S., Raj, N., Vijayvergia, N., Dasari, A., O'Reilly, E. M., Meyerhardt, J. A., Wolin, E. M., Halfdanarson, T. R., & Chan, J. A. (2026). Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). Endocrine-Related Cancer, 33(1). https://doi.org/10.1530/erc-25-0415

Vancouver

Strosberg JR, Zemla T, Geyer S, Pulsipher S, Ou FS, Behr S, et al. Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). Endocrine-Related Cancer. 2026;33(1). doi:10.1530/erc-25-0415

BibTeX
@article{Strosberg2026,
  author = {Strosberg, Jonathan R and Zemla, Tyler and Geyer, Susan and Pulsipher, Sydney and Ou, Fang-Shu and Behr, Spencer and Raj, Nitya and Vijayvergia, Namrata and Dasari, Arvind and O'Reilly, Eileen M and Meyerhardt, Jeffrey A and Wolin, Edward M and Halfdanarson, Thorvardur R and Chan, Jennifer A},
  title = {Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602)},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  volume = {33},
  number = {1},
  doi = {10.1530/erc-25-0415}
}
Kostenlos starten →